百济神州(06160.HK)公布百泽安用於治疗二线或三线非小细胞肺癌之临床试验中期分析结果
百济神州(06160.HK)公布,於今年4月12日在美国癌症研究协会(AACR)2021年年会上的一项口头报告中公布了其抗PD-1抗体百泽安(替雷利珠单抗)对比多西他赛针对二线或三线局部晚期或转移性非小细胞肺癌(NSCLC)患者的全球3期临床试验的中期分析结果。基於此项试验结果的新适应症上市申请(sBLA)已於2021年3月在中国获受理,目前正在接受审评。
公司指,结果证明百泽安有望为二线或三线局部晚期或转移性NSCLC患者带来生存益处,这与集团在去年的ASCO以及ESMO年会上公布针对初治患者的两项试验结果相一致。此外,百泽安总体耐受,与先前在其他多项肿瘤中公布的结果和已知风险相符。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.